Amifostine

What is Amifostine?

Amifostine is a powerful cytoprotective agent used in oncology to protect healthy cells from the damaging effects of certain cancer treatments. Originally developed as a radioprotectant for the military, it has found a crucial role in mitigating chemotherapy-induced toxicity and the adverse effects of radiation therapy. Marketed under the brand name Ethyol, Amifostine is a prodrug, meaning it is inactive until metabolized in the body. Its primary function is to selectively shield non-cancerous tissues, thereby allowing patients to better tolerate aggressive cancer treatments and potentially improve their quality of life during therapy.

This medication is administered intravenously and is specifically indicated to reduce the severity of side effects such as kidney damage (nephrotoxicity) caused by platinum-based chemotherapy drugs like cisplatin, and dry mouth (xerostomia) resulting from radiation to the head and neck area. By offering a protective barrier to healthy cells, Amifostine helps maintain organ function and reduces the debilitating symptoms that often accompany cancer treatment, making it a valuable adjunct therapy.

How Does it Work?

The mechanism of action of Amifostine is quite sophisticated and selective. As a prodrug, Amifostine is enzymatically dephosphorylated by alkaline phosphatases, which are present in higher concentrations in normal tissues compared to tumor cells, especially in areas like the kidneys. This process converts Amifostine into its active free thiol metabolite, WR-1065. It is this active metabolite that confers the cytoprotective effects.

• Selective Uptake and Activation: Normal cells have a more efficient transport system and higher levels of alkaline phosphatase activity, leading to greater uptake and activation of Amifostine. Tumor cells, often having lower pH and reduced phosphatase activity, take up and activate less of the drug, thus minimizing protection of cancer cells.
• Free Radical Scavenging: WR-1065 acts as a potent scavenger of free radicals. Many chemotherapy agents and radiation therapy exert their cytotoxic effects by generating reactive oxygen species (ROS) that damage DNA, proteins, and lipids. By neutralizing these free radicals, WR-1065 reduces oxidative stress and cellular damage in healthy tissues.
• DNA Protection and Repair: The active metabolite can also bind to and protect cellular macromolecules, including DNA, from damage induced by alkylating agents (a class of chemotherapy drugs) and radiation. It can also enhance DNA repair mechanisms in normal cells.
• Detoxification: WR-1065 can interact with and detoxify certain reactive metabolites of chemotherapy drugs, further reducing their harmful effects on healthy cells.

This selective protection is key to Amifostine's utility, allowing clinicians to administer optimal doses of chemotherapy and radiation with reduced collateral damage to the patient's body.

Medical Uses

Amifostine's approved medical uses are specific and target significant side effects of cancer treatment:

• Reduction of Cisplatin-Induced Nephrotoxicity: One of the primary indications for Amifostine is to reduce the cumulative renal toxicity associated with repeated doses of cisplatin in patients with advanced ovarian cancer or non-small cell lung cancer. Cisplatin is highly effective but can cause severe kidney damage, which can limit its use. Amifostine helps protect kidney cells, allowing for continued effective treatment.
• Reduction of Radiation-Induced Xerostomia: Amifostine is also indicated to reduce the incidence of moderate to severe xerostomia (dry mouth) in patients undergoing post-operative radiation therapy for head and neck cancer. Radiation to this area often damages salivary glands, leading to chronic dry mouth, which severely impacts quality of life, speech, and eating. By protecting the salivary glands, Amifostine helps preserve their function.

While these are the main approved uses, Amifostine has been investigated for other potential cytoprotective roles, including reducing mucositis, esophagitis, neurotoxicity, and myelosuppression associated with various chemotherapy regimens and radiation fields. However, its use in these areas is often off-label or still under clinical investigation.

Dosage

The administration of Amifostine requires careful medical supervision and adherence to specific protocols, typically in a clinical setting. It is administered intravenously (IV) and the dosage varies depending on the indication:

• For Reduction of Cisplatin-Induced Nephrotoxicity: The recommended dose is typically 910 mg/m² administered as a 15-minute intravenous infusion, starting 30 minutes prior to chemotherapy. It is crucial to monitor blood pressure carefully during and after administration due to the risk of hypotension.
• For Reduction of Radiation-Induced Xerostomia: The recommended dose is 200 mg/m² administered as a 3-minute intravenous infusion, starting 15-30 minutes prior to daily fractions of radiation therapy. Again, blood pressure monitoring is essential.

Dosing adjustments may be necessary based on the patient's blood pressure, renal function, and overall tolerance. Pre-treatment hydration and antiemetics may be required. It is imperative that Amifostine is administered by healthcare professionals experienced in oncology and chemotherapy administration.

Side Effects

Like all medications, Amifostine can cause side effects, although its purpose is to reduce the side effects of other treatments. The most common and significant side effect is transient hypotension (a drop in blood pressure), which can be severe.

Common Side Effects:

• Hypotension: This is the most frequent and potentially serious side effect. It usually occurs during or shortly after infusion and is often managed by slowing or interrupting the infusion, administering intravenous fluids, or positioning the patient appropriately. Blood pressure must be monitored closely before, during, and after administration.
• Nausea and Vomiting: These can occur but are often managed with antiemetic medications.
• Flushing/Warmth: Patients may experience a sensation of warmth or flushing.
• Dizziness/Somnolence: Lightheadedness or drowsiness can occur, often related to hypotension.
• Allergic Reactions: Rarely, more severe hypersensitivity reactions, including anaphylaxis, can occur.

Patients should report any unusual or severe symptoms to their healthcare provider immediately. Given the risk of hypotension, Amifostine is typically administered with the patient in a supine position and with close cardiovascular monitoring.

Drug Interactions

While Amifostine is generally well-tolerated with most cancer therapies, there are a few potential drug interactions to be aware of, primarily related to its most prominent side effect, hypotension.

• Antihypertensive Medications: Patients taking medications for high blood pressure (antihypertensives) should be carefully monitored. Amifostine can cause a transient drop in blood pressure, and combining it with antihypertensives may potentiate this effect, leading to more severe or prolonged hypotension. In some cases, temporary discontinuation of antihypertensive medications for 24 hours prior to Amifostine administration may be considered, but this decision must be made by a physician based on the patient's individual cardiovascular risk.
• Other Medications Affecting Blood Pressure: Caution is advised when Amifostine is used concurrently with other drugs that can cause a drop in blood pressure.

It is crucial for patients to provide their healthcare team with a complete list of all medications, supplements, and herbal remedies they are taking to identify and manage potential interactions.

FAQ

What is Amifostine used for?

Amifostine is used to reduce the harmful side effects of certain cancer treatments. Specifically, it helps protect kidneys from damage caused by cisplatin chemotherapy and reduces dry mouth (xerostomia) in patients receiving radiation therapy for head and neck cancer.

How is Amifostine administered?

Amifostine is administered intravenously (into a vein) by a healthcare professional in a clinical setting. The infusion duration and timing depend on whether it's being used for chemotherapy protection or radiation protection.

What are the main side effects of Amifostine?

The most common and significant side effect is a temporary drop in blood pressure (hypotension). Other common side effects include nausea, vomiting, flushing, and dizziness. Close monitoring of blood pressure is essential during administration.

Is Amifostine a form of chemotherapy?

No, Amifostine is not a chemotherapy drug. It is a cytoprotective agent, meaning it works to protect healthy cells from the damaging effects of chemotherapy and radiation, rather than directly targeting cancer cells.

Products containing Amifostine are available through trusted online pharmacies. You can browse Amifostine-based medications at ShipperVIP or Medicenter.

Summary

Amifostine is a vital cytoprotective agent in modern oncology, playing a crucial role in mitigating the severe side effects associated with certain chemotherapy regimens and radiation therapy. By selectively protecting healthy tissues through its active metabolite, WR-1065, it helps reduce cisplatin-induced nephrotoxicity and radiation-induced xerostomia. While its administration requires careful monitoring for potential hypotension, Amifostine enables patients to better tolerate aggressive cancer treatments, contributing significantly to their overall well-being and treatment adherence. Its unique mechanism of action underscores its importance in supportive cancer care, allowing for more effective and less debilitating therapeutic interventions.